ROC analysis further verified that MD2 could serve as a sensitive indicator to predict the 1-year, 3-year, and 5-year survival rates of the patients, indicating the value of MD2 as a prognostic biomarker for gliomas. The gene discussed is LY96; the disease is glioma.